Adverse events in patients with castration-resistant prostate cancer treated with ra-223: a retrospective pharmacovigilance study.

April
SunMonTueWedThuFriSat
303112345678910111213141516171819202122232425262728293012345678910
April
SunMonTueWedThuFriSat
303112345678910111213141516171819202122232425262728293012345678910
Copyright © Ark Medical Solutions Inc. All Rights Reserved.